Tirabrutinib

Phase 3

Deciphera Pharmaceuticals, Inc. (DCPH)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Feb '27

DCPHPDUFA

Phase 3

FDA PDUFA Date Tirabrutinib

Tirabrutinib• relapsed or refractory PCNSL

Feb 2027~Estimated

Source

00%

Competitive Landscape

0 competitors in Relapsed/Refractory Primary Central Nervous System Lymphoma

View Full Landscape

Drug Information

Target Indication

Relapsed/Refractory Primary Central Nervous System Lymphoma

Clinical Trial

NCT07104032

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

DCPH

Deciphera Pharmaceuticals, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

RipretinibPhase 3

GIST

VimseltinibPhase 3

Chronic Graft-Versus-Host Disease (cGVHD)

DCC-2618Phase 3

Gastrointestinal Stromal Tumors

SapablursenPhase 3

Polycythemia Vera

SunitinibPhase 3

Gastrointestinal Stromal Tumors

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts